{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T11:15:09Z","timestamp":1791976509031,"version":"4.4.0"},"reference-count":26,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,2,22]],"date-time":"2023-02-22T00:00:00Z","timestamp":1677024000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Methotrexate (MTX) is an essential anti-rheumatic drug used to treat rheumatoid arthritis (RA). Prevention or management of adverse reactions, including interstitial lung disease (ILD), hepatotoxicity, myelosuppression, and infection, remains fundamental for safe MTX therapy. Using the Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) (JAPIC AERS), we performed disproportionality analyses of adverse events related to MTX use and the impact of concomitant medications. Upon analyzing all reported cases in FAERS between 1997 and 2019, the crude reporting odds ratios (cRORs; 95% confidence intervals) for ILD, hepatotoxicity, myelosuppression, and tuberculosis (TB) in relation to MTX use were 4.00 (3.83\u20134.17), 1.99 (1.96\u20132.02), 3.66 (3.58\u20133.74), and 7.97 (7.65\u20138.3), respectively. Combining MTX with folic acid (FA) or tumor necrosis factor-alpha inhibitors (TNFis) tended to reduce cRORs for these adverse events (except for TB). Multiple logistic regression analysis in patients with RA was conducted to calculate adjusted reporting odds ratios (aRORs) for age, sex, and MTX treatment patterns (MTX alone and combined with FA and TNFi). Higher age (except for hepatotoxicity) and male sex were significantly associated with adverse events. Combining FA or TNFi with MTX reduced aRORs for MTX-related hepatotoxicity and myelosuppression; in contrast, the effect of FA was not obvious in ILD or TB. Although studies assessing spontaneous reporting systems have limitations such as reporting bias, data from our logistic regression analysis demonstrated that adding FA to MTX-based therapy could help reduce the dose-dependent adverse events of MTX, thereby providing clinical evidence that supports the beneficial effect of FA. This study also demonstrated the usefulness of FAERS in comparing adverse events based on treatment patterns.<\/jats:p>","DOI":"10.3389\/fphar.2023.1030832","type":"journal-article","created":{"date-parts":[[2023,2,22]],"date-time":"2023-02-22T03:30:03Z","timestamp":1677036603000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":25,"title":["Methotrexate-related adverse events and impact of concomitant treatment with folic acid and tumor necrosis factor-alpha inhibitors: An assessment using the FDA adverse event reporting system"],"prefix":"10.3389","volume":"14","author":[{"given":"Kenji","family":"Onda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Honma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Masuyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,2,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1586\/1744666X.2013.811173","article-title":"Lung involvement and drug-induced lung disease in patients with rheumatoid arthritis","volume":"9","author":"Atzeni","year":"2013","journal-title":"Expert Rev. Clin. Immunol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1002\/pds.1742","article-title":"Quantitative signal detection using spontaneous ADR reporting","volume":"18","author":"Bate","year":"2009","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"B3","doi-asserted-by":"publisher","first-page":"e000371","DOI":"10.1136\/rmdopen-2016-000371","article-title":"Systematic review and network meta-analysis of the efficacy and safety of tumour necrosis factor inhibitor-methotrexate combination therapy versus triple therapy in rheumatoid arthritis","volume":"3","author":"Fleischmann","year":"2017","journal-title":"RMD Open"},{"key":"B4","doi-asserted-by":"publisher","first-page":"238","DOI":"10.3389\/fmed.2019.00238","article-title":"Methotrexate-associated pneumonitis and rheumatoid arthritis-interstitial lung disease: Current concepts for the diagnosis and treatment","volume":"6","author":"Fragoulis","year":"2019","journal-title":"Front. Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1331\/JAPhA.2013.12218","article-title":"Dabigatran-dronedarone interaction in a spontaneous reporting system","volume":"53","author":"Gandhi","year":"2013","journal-title":"J. Am. Pharm. Assoc."},{"key":"B6","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1136\/ard.2008.089276","article-title":"Association of methotrexate and tumour necrosis factor antagonists with risk of infectious outcomes including opportunistic infections in the CORRONA registry","volume":"69","author":"Greenberg","year":"2010","journal-title":"Ann. Rheum. Dis."},{"key":"B7","doi-asserted-by":"publisher","first-page":"E15","DOI":"10.3390\/jcm8010015","article-title":"Risk of infection with methotrexate therapy in inflammatory diseases: A systematic review and meta-analysis","volume":"8","author":"Ibrahim","year":"2018","journal-title":"J. Clin. Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"20359","DOI":"10.1038\/s41598-019-56900-2","article-title":"Concomitant febuxostat enhances methotrexate-induced hepatotoxicity by inhibiting breast cancer resistance protein","volume":"9","author":"Ikemura","year":"2019","journal-title":"Sci. Rep."},{"key":"B9","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1136\/amiajnl-2013-001612","article-title":"Mining clinical text for signals of adverse drug-drug interactions","volume":"21","author":"Iyer","year":"2014","journal-title":"J. Am. Med. Inf. Assoc. JAMIA"},{"key":"B10","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1155\/2013\/527912","article-title":"Methotrexate-induced pulmonary toxicity","volume":"20","author":"Jakubovic","year":"2013","journal-title":"Can. Respir. J."},{"key":"B11","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software \u201cEZR\u201d for medical statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transpl."},{"key":"B12","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/S0140-6736(04)15640-7","article-title":"Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: Double-blind randomised controlled trial","volume":"363","author":"Klareskog","year":"2004","journal-title":"Lancet lond. Engl."},{"key":"B13","doi-asserted-by":"publisher","first-page":"145","DOI":"10.11256\/jjdi.17.145","article-title":"Adverse event signals of interstitial lung disease in the FDA adverse event reporting system (FAERS) database and the Japanese adverse drug event report (JADER) database","volume":"17","author":"Matsui","year":"2015","journal-title":"Iyakuhin Johogaku"},{"key":"B14","doi-asserted-by":"publisher","first-page":"2050312120918264","DOI":"10.1177\/2050312120918264","article-title":"Analysis of drug-induced interstitial lung disease using the Japanese Adverse Drug Event Report database","volume":"8","author":"Matsumoto","year":"2020","journal-title":"SAGE Open Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"2286","DOI":"10.1111\/bcp.14641","article-title":"Risk of haematological events and preventive effect of folic acid in methotrexate users with chronic kidney disease and rheumatoid arthritis: Analysis of the Japanese Adverse Drug Event Report database","volume":"87","author":"Mitsuboshi","year":"2021","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"145632","DOI":"10.1172\/jci.insight.145632","article-title":"Striatal TRPV1 activation by acetaminophen ameliorates dopamine D2 receptor antagonist-induced orofacial dyskinesia","volume":"6","author":"Nagaoka","year":"2021","journal-title":"JCI Insight"},{"key":"B17","doi-asserted-by":"publisher","first-page":"bbab347","DOI":"10.1093\/bib\/bbab347","article-title":"Detection algorithms and attentive points of safety signal using spontaneous reporting systems as a clinical data source","volume":"22","author":"Noguchi","year":"2021","journal-title":"Brief. Bioinform."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1001\/jamaoncol.2017.4526","article-title":"EGFR-TKI-Associated interstitial pneumonitis in nivolumab-treated patients with non-small cell lung cancer","volume":"4","author":"Oshima","year":"2018","journal-title":"JAMA Oncol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"796","DOI":"10.7150\/ijms.6048","article-title":"Data mining of the public version of the FDA adverse event reporting system","volume":"10","author":"Sakaeda","year":"2013","journal-title":"Int. J. Med. Sci."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.3899\/jrheum.130738","article-title":"Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis","volume":"41","author":"Shea","year":"2014","journal-title":"J. Rheumatol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"CD000951","DOI":"10.1002\/14651858.CD000951.pub2","article-title":"Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis","volume":"2013","author":"Shea","year":"2013","journal-title":"Cochrane Database Syst. Rev."},{"key":"B22","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1248\/bpb.b14-00191","article-title":"Analysis of the interaction between clopidogrel, aspirin, and proton pump inhibitors using the FDA adverse event reporting system database","volume":"38","author":"Suzuki","year":"2015","journal-title":"Biol. Pharm. Bull."},{"key":"B23","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/s00296-009-0931-6","article-title":"Interstitial pneumonitis associated with infliximab therapy without methotrexate treatment","volume":"30","author":"Taki","year":"2009","journal-title":"Rheumatol. Int."},{"key":"B24","doi-asserted-by":"publisher","first-page":"135","DOI":"10.11256\/jjdi.21.135","article-title":"Basic dos and don\u2019ts in applying signal detection methods to spontaneous reporting systems databases","volume":"21","author":"Urushihara","year":"2020","journal-title":"Jpn. J. Drug Inf."},{"key":"B25","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1007\/s002280000215","article-title":"Detecting drug-drug interactions using a database for spontaneous adverse drug reactions: An example with diuretics and non-steroidal anti-inflammatory drugs","volume":"56","author":"van Puijenbroek","year":"2000","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"206ra140","DOI":"10.1126\/scitranslmed.3006548","article-title":"Systems pharmacology of adverse event mitigation by drug combinations","volume":"5","author":"Zhao","year":"2013","journal-title":"Sci. Transl. Med."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1030832\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,22]],"date-time":"2023-02-22T03:30:07Z","timestamp":1677036607000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1030832\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,22]]},"references-count":26,"alternative-id":["10.3389\/fphar.2023.1030832"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2023.1030832","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,22]]},"article-number":"1030832"}}